GATA3 and neoplasm: Prior to this study, Hodgson et al. used the same antibodies, identifying 85.2% of tumours as luminal (KRT5/6−, GATA3+) and 14.8% as basal (KRT5/6+, GATA3−); curiously, the basal subtype showed better disease-specific survival, higher CD8+ lymphocyte counts, and increased PD-1 and PD-L1 expression [41].